BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 12, 2001
View Archived Issues
Chiron sells gene therapy manufacturing facility to Cell Genesys; retains product rights
Read More
AeroGen reports product update
Read More
Vasogen begins immune modulation therapy clinical trials in CLL
Read More
NCI and Biovest may enter B-cell lymphoma vaccine collaboration
Read More
Centaur's rheumatoid arthritis drug advances to preclinical development
Read More
Diversa and IntraBiotics join forces to identify novel antiinfectives
Read More
Sanofi-Synthelabo to market Leuprogel in the U.S. and Canada
Read More
Voluntary suspension of Oxygent phase III trial announced by Alliance
Read More
Millennium/Wyeth-Ayerst antiinfective alliance identifies first preclinical candidate
Read More
Protherics provides interim update on product development
Read More
Phase III compound for liver diseases licensed by Interneuron
Read More
MMP inhibition as a therapeutic approach to preventing intracerebral hemorrhage after tPA therapy
Read More
Novazyme seeks orphan drug designation for MPS I therapy
Read More
Progress report on Metabolic's obesity and diabetes programs
Read More
Inhibitors of p38 kinase and their use disclosed by Scios
Read More
Recent patent covers hydroxamic acid-based MMP inhibitors and their therapeutic use
Read More
More on bacterial enzyme inhibitors under study at GlaxoSmithKline
Read More
Immunosuppressants acting as P2X7 receptor antagonists claimed by AstraZeneca
Read More
Soluble inhibitors of protein kinase C designed at AstraZeneca for wide range of disorders
Read More
Provalis obtains U.K. marketing rights to Pennsaid topical solution
Read More
New ACAT inhibitors in development at Sumitomo
Read More
Prototypical selective mglu5 antagonist displays anxiolytic-like effects
Read More
Abgenix further extends antibody collaborations with Pfizer, Amgen
Read More
Nonprostanoid PGI2 agonist with antiplatelet effects and favorable PK profile
Read More
Triptolide prodrug is highly effective in lethal murine GVHD model
Read More
Theratechnologies seeks clearance to initiate two additional trials with ThGRF1-44
Read More
Phase II trial begins with Idec's antipsoriatic antibody IDEC-114
Read More
SciClone commences phase II study of Zadaxin as treatment for hepatocellular carcinoma
Read More